Australija - anglų - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii,von willebrand factor -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - factor viii inhibitor bypassing fraction, quantity: 1000 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; sodium chloride - feiba-nf is indicated for routine prophylaxis, control of spontaneous bleeding episodes and use in surgery in haemophilia a or b patients with inhibitors.

Malta - anglų - Malta Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 250 iu von willebrand factor, human 190 iu - antihemorrhagics

Malta - anglų - Malta Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 500 iu von willebrand factor, human 375 iu - antihemorrhagics

Malta - anglų - Malta Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 1000 iu von willebrand factor, human 750 iu - antihemorrhagics

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

grifols usa, llc - human coagulation factor viii/von willebrand factor complex (unii: 5t6b772r4q) (human coagulation factor viii/von willebrand factor complex - unii:5t6b772r4q) - human coagulation factor viii/von willebrand factor complex 250 [iu] in 5 ml - alphanate, (antihemophilic factor/von willebrand factor complex [human]), is indicated for: - control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor viii (fviii) deficiency due to hemophilia a. - surgical and/or invasive procedures in adult and pediatric patients with von willebrand disease (vwd) in whom desmopressin (ddavp) is either ineffective or contraindicated.  it is not indicated for patients with severe vwd (type 3) undergoing major surgery. alphanate is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components [see adverse reactions (6) ]. pregnancy category c.  animal reproduction studies have not been conducted with alphanate.  it is also not known whether alphanate can cause fetal harm when administered to a pregnant woman or affect reproductive capacity.  alphanate should be given to a pregnant woman only if clearly needed.   no human o

Izraelis - anglų - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Izraelis - anglų - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Izraelis - anglų - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1000 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - von willebrand factor; factor viii - powder and solvent for solution for injection - 500unit ; 250unit